Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Humacyte
MedTech
FDA approves Humacyte’s off-the-shelf artery for trauma repairs
Humacyte’s tissue-based Symvess is designed to be universally implantable for patients facing the loss of a limb.
Conor Hale
Dec 23, 2024 10:36am
Humacyte's regenerative tissues ace vascular trauma trial
Sep 12, 2023 10:53am
Insulet tapped to replace SVB on S&P 500
Mar 13, 2023 3:20pm
Biogen taps new board chair—Chutes & Ladders
Mar 10, 2023 9:30am
Fierce Biotech launches layoff tracker—Chutes and Ladders
Apr 8, 2022 9:30am
Humacyte takes the SPAC track to Wall Street
Feb 17, 2021 8:20am
